Fig. 3 | Oncogene

Fig. 3

From: Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3

Fig. 3

miR-483-3p reverses EMT in gefitinib-resistant cells. a–c Indicated cells were transiently transfected with miR-483-3p mimic (mimic), negative control (NC), miR-483-3p inhibitor (inhibitor), or inhibitor negative control (INC) as indicated. a, b Western blot analysis of the expression of EMT markers. c Immunostaining analysis of vimentin (red, top panel) and E-cadherin (red, bottom panel). d Western blot analysis of E-cadherin and vimentin in HCC827 xenograft tumors treated with gefitinib daily for 6–8 weeks until tumors regrown (resistant) or saline for 1 week (sensitive) (left panel). Western blot analysis of E-cadherin and vimentin in regrown HCC827 xenograft tumors (resistant HCC827) (middle panel) or HCC827GR-xenograft tumors (right panel) intratumorally injected with agomir-483-3p mimic (mimic) or agomir-NC (NC)

Back to article page